MedDataX Logo

DuoTrav® Eye Drops As Replacement Therapy Program

NCT ID: NCT00828906

Last Updated: 2012-09-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

128 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the effectiveness of DuoTrav Eye Drops in gaining or maintaining control of target Intraocular Pressures (tIOP) in patients diagnosed with, and being treated for, open-angle glaucoma (OAG) or ocular hypertension (OH).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Open-angle Glaucoma Ocular Hypertension

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Glaucoma IOP DuoTrav

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

DuoTrav

Group Type EXPERIMENTAL

DuoTrav

Intervention Type DRUG

DuoTrav Eye Drops

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DuoTrav

DuoTrav Eye Drops

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with OAG or OH for whom single agent therapy provides insufficient intraocular pressure reduction

Exclusion Criteria

* None
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Alcon Research

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Contact Alcon for Trial Locations

Beijing, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DART-2

Identifier Type: -

Identifier Source: org_study_id